Biomedical Engineering Reference
In-Depth Information
Müller RH, Becker R, Kruss B, Peters K (1999) Pharmaceutical nanosuspensions for medicament
administration as systems with increased saturation solubility and rate of solution. United States
Patent 5,858,410
Müller RH, Mäder K, Krause K (2000) Method for controlled production of ultrafine micro-
particles and nanoparticles. PCT/EP2000/006535
Müller RH, Lück M, Kreuter J (2001) Medicament excipient particles for tissue-specific
application of a medicament. United States Patent 6,288,040
Müller RH, Jacobs, C., Kayser, O. (2003) DissoCubes - a novel formulation for poorly soluble and
poorly bioavailable drugs. In: Rathbone MJ, Hadgraft, J., Roberts, M. S. (ed) Modified-Release
Drug Delivery Systems. Marcel Dekker, pp 135-149
National Nanotechnology Initiative (NNI) (2001) What is Nanotechnology?
http://www.nano.gov
.
Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November
2009 on cosmetic products (2009). Official Journal of the European Union L342:59-209
Pardeike J, Müller RH (2010) Nanosuspensions: a promising formulation for the new phospholipase
A2 inhibitor PX-18. Int J Pharm 391 (1-2):322-329
Petersen RD (2006) Nanocrystals for use in topical fomulations and method of production thereof.
PCT/EP2007/009943
Rabinow B, Kipp J, Papadopoulos P, Wong J, Glosson J, Gass J, Sun CS, Wielgos T, White R,
Cook C, Barker K, Wood K (2007) Itraconazole IV nanosuspension enhances efficacy through
altered pharmacokinetics in the rat. Int J Pharm 339 (1-2):251-260
Roubin R, Zolla-Pazner S (1979) Markers of macrophage heterogeneity. I. Studies of macrophages
from various organs of normal mice. European Journal of Immunology 9 (12):972-978
Schöler N (2001) Solid lipid nanoparticles (SLN) and nanosuspensions: In vitro cytotoxicity and
therapeutic use in the model of reactivating toxoplasmosis in mice. Dissertation, PhD thesis,
Freie Universität Berlin,
Schöler N, Krause C, Kayser O, Müller RH, Hahn H, Liesenfeld O In vitro efficacy of atovaquone
nanosuspensions against toxoplasma gondii. In: 3rd World Meeting on Pharmaceutics,
Biopharmaceutics and Pharmaceutical Technology APGI/APV, Berlin, 2000. pp 437-438
Schöler N, Krause, K., Kayser, O., Müller, R. H., Hartwig, H., Hahn, H., Liesenfeld, O. (2001)
Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of
reactivated toxoplasmosis. Antimicrobial Agents & Chemotherapy:1771-1779
Schroeder U, Sommerfeld P, Sabel BA (1998) Efficacy of oral dalargin-loaded nanoparticle
delivery across the blood-brain barrier. Peptides 19 (4):777-780
Smith A, Hunneyball lM (1986) Evaluation of poly(lactic acid) as a biodegradable drug delivery
system for
parenteral administration. International
Journal
of
Pharmaceutics
30
(2-3):215-220
Staedtke V, Brahler M, Müller A, Georgieva R, Bauer S, Sternberg N, Voigt A, Lemke A, Keck C,
Möschwitzer J, Bäumler H (2010) In vitro inhibition of fungal activity by macrophage-mediated
sequestration and release of encapsulated amphotericin B nanosupension in red blood cells.
Small 6 (1):96-103
Strachan EB (1981) Case report--suspected anaphylactic reaction to Cremophor El. SAAD Dig 4
(9):209
Szejtli J (1988) Cyclodextrin technology. Kluwer Academic Publishers,
Wilkins DJ, Myres PA (1966) Studies on the relationship betweeen the electrophoretic properties
of colloides and their blood clearance and organ distribution in the rat. British Journal of
Experimental Pathology 47:568-576
Zirconium dioxide. Wikipedia
Search WWH ::
Custom Search